Agilent Technologies, a global analytical and clinical technology provider, has acquired BIOVECTRA — a North American CDMO.
The USD $925m transaction will bolster Agilent’s end-to-end manufacturing capabilities in the production of biologics, high-potency APIs and molecules for targeted therapeutics.
Enhancing CDM capabilities
The strategic move will build on Agilent’s CDMO specialisation by boosting its service portfolio — including the manufacture of highly popular therapeutics such as GLP-1 medications and antibody drug conjugates (ADCs).
It will also bring together the gene editing expertise of both companies, allowing customers to access a wide range of technologies and biologic capabilities related to this area under one roof.
Both BIOVECTRA and Agilent are fully integrated CDMOs with cGMP facilities that can manufacture, process and package APIs.
Agilent’s President and CEO Padraig McDonnell, said: "BIOVECTRA's manufacturing capabilities further expand Agilent's end-to-end biopharma offerings into new growth vectors, including workflows that seamlessly integrate analytical instrumentation, consumables and a wide range of lab services.”
The transaction is subject to customary closing conditions — including receipt of regulatory approvals — and is expected to close before 2025.
Upon close, BIOVECTRA will become part of the Agilent Diagnostics and Genomics Group.
